Author Archives: Patrick Clinton
The Real China Strategy
There’s a lot of talk these days about India and China as potential markets and as sources for cheap manufacturing and R&D. But the real potential of these countries is far more interesting: As China and India (and Brazil, Russia, and Korea) learn to create new products, they’re going to do it at price [...]
Posted in Biotech, Deals, Emerging Markets, Strategy Tagged Abe Abuchowski, Biotech, China, PEGylation, Pharma, Prolong 10 Comments
"Side Effects" and "The Normalization of Suspicion"
In today’s Wall Street Journal, Mark Herrmann, an attorney with Jones Day, co-proprietor of the Drug and Device Law blog, as well as an occasional contributor to Pharm Exec, has a lively review of Alison Bass’ Side Effects, a new book that tells the story of the campaign against Paxil.
His bottom line is a [...]
Posted in Corporate Responsibility, Safety Tagged Alison Bass, Drug and Device Law blog, GSK, Jones Day, Mark Herrmann, Paxil, Side Effects Leave a comment
Gene Therapy Files for Approval
An estimated one thousand clinical trials have been conducted for gene therapies in the past 20 years, but to date, not a single drug has made it to FDA approval. However, we may be a step closer as Introgen today announced that it has filed applications with FDA and EMEA for marketing approval of Advexin, [...]
Posted in Gene therapy, R&D Leave a comment
Biotech Watch: Dual Opiates, Certified Pigs
Just back from BIO, where two of the most interesting conversations I had were with companies from Down Under.
First was Paul Tan, CEO of Living Cell Technologies, which is officially headquartered in Melbourne Australia, but operates out of Auckland, New Zealand. The company is developing a diabetes therapy that involves implanting specially encapsulated pig pancreas [...]

Coming Soon: Cancer Wars